| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.0049 | 1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0036 | 1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0026 | 1 |